Global Liver Transplant Rejection Therapeutics Pipeline Report H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Liver Transplant Rejection - Pipeline Review, H1 2017" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Liver Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Liver Transplant Rejection - Overview
  4. Liver Transplant Rejection - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Liver Transplant Rejection - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Liver Transplant Rejection - Companies Involved in Therapeutics Development
  • Astellas Pharma Inc
  • Biogen Inc
  • Conatus Pharmaceuticals Inc
  • Dompe Farmaceutici SpA
  • Novartis AG
  • RedHill Biopharma Ltd

For more information about this report visit http://www.researchandmarkets.com/research/r76963/liver_transplant

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Liver and Kidney Disorders Drugs , Immunosuppressive Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Liver and Kidney Disorders Drugs , Immunosuppressive Drugs